Psilocybin reduces symptoms of major depression: The Lancet

Published Date: 04 Mar 2023

A new study by Robin von Rotz and his team found that moderate doses of psilocybin for at least two weeks reduced symptoms of depression...

Read Full News

Latest News

Mosquito saliva may hold clues to fighting chikungunya inflammation

Scientists from the A*STAR Infectious Diseases Labs (A*STAR IDL) have uncovered a surprising mechanism showing how mosquito saliva can alter the human body's immune response during chikungunya virus (CHIKV) infection, contributing ...

Less than half of schoolkids at risk of food anaphylaxis in England prescribed adrenaline 'antidote'

Less than half of schoolchildren in England who are at risk of a serious and potentially life-threatening allergic reaction (anaphylaxis) to food were prescribed the antidote—an adrenaline [epinephrine] autoinjector, or ...

Recurrence-free survival longer with nivolumab than ipilimumab in melanoma: Study

For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England Journal of Medicine to coincide ...

Decoding the T cell burst: Signature genes predict T cell expansion in cancer immunotherapy

The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and mechanisms that drive this ...

Triplet combinations of immunotherapy and targeted treatments as first-line therapy for advanced renal cell carcinoma

KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced clear cell renal cell carcinoma ...

Research targets treatment resistance in neuroendocrine tumors

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented at the ...

Todays Updates

Higher levels of HIF2α found to slow down aggressive childhood cancer

Neuroblastoma is a type of cancer that affects the sympathetic nervous system in young children and is often difficult to treat, especially when the tumor cells carry multiple copies of the MYCN gene.

Report provides global picture of wide inequalities in care for women's cancers

One in five women with breast or cervical cancer in low- and middle-income countries (LMICs) are diagnosed at an early stage, compared with more than one in three in high-income countries (HICs), new research suggests. For ...

Todays Updates

Higher levels of HIF2α found to slow down aggressive childhood cancer

Neuroblastoma is a type of cancer that affects the sympathetic nervous system in young children and is often difficult to treat, especially when the tumor cells carry multiple copies of the MYCN gene.

Report provides global picture of wide inequalities in care for women's cancers

One in five women with breast or cervical cancer in low- and middle-income countries (LMICs) are diagnosed at an early stage, compared with more than one in three in high-income countries (HICs), new research suggests. For ...

Latest News

Scientists from the A*STAR Infectious Diseases Labs (A*STAR IDL) have uncovered a surprising mechanism showing how mosquito saliva can alter the human body's immune response during chikungunya virus (CHIKV) infection, contributing ...

Less than half of schoolchildren in England who are at risk of a serious and potentially life-threatening allergic reaction (anaphylaxis) to food were prescribed the antidote—an adrenaline [epinephrine] autoinjector, or ...

For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England Journal of Medicine to coincide ...

The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and mechanisms that drive this ...

KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced clear cell renal cell carcinoma ...

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented at the ...

News All Time

Supercharging immune cells to fight drug resistant bowel cancer

Scientists at University College London have engineered a rare type of immune cell to kill slow-growing bowel cancer cells that are resistant to current therapies, a breakthrough that could lead to new treatments in the future.

Crucial protein enables immune system memory

Researchers at the University of Missouri School of Medicine have recently found that a certain protein may have a large influence on how the immune system functions.

Cancer patients' thymic health is linked to their response to immunotherapy 

In cancer patients, the health of the thymus—a key part of the body's immune system—is associated with the outcomes these patients experience after immune checkpoint inhibitor treatment, according to an international ...

How bacteria in tumors drive treatment resistance in cancer

Researchers from The University of Texas MD Anderson Cancer Center have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The ...

Biomarker analysis reveals clues to long-term survival in glioblastoma patients treated with SurVaxM

Results of a study led by researchers at Roswell Park Comprehensive Cancer Center are shedding light on why some newly diagnosed glioblastoma patients survive longer than others after receiving standard treatment in conjunction ...

Modified virus boosts cancer vaccine effectiveness in mouse experiments

Could a future vaccine against cancer be made better by an immune-boosting virus? Very likely, say Canadian scientists, who've proven its effectiveness in experiments on mice.

Child's atopic dermatitis linked to maternal depression scores

Child atopic dermatitis (AD) is associated with higher maternal depression scores, according to a study published online Oct. 5 in the Journal of the American Academy of Dermatology.

Conversion of IgG antibodies to IgM broadens antibacterial activity

Researchers at UMC Utrecht have discovered that converting monoclonal antibodies from the IgG to the IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant bacterial pathogens. The ...

Novel combination therapy shows promise for aggressive lymphoma resistant to immunotherapy

A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, shows promising results in patients with relapsed or ...

Immune cell subtype in multiple sclerosis patients may enable targeted treatment

Multiple sclerosis, which affects around one in 500 people in Switzerland, is an autoimmune disease in which immune cells attack the central nervous system, causing irreversible damage. Current treatments involve blocking ...

Large cohort study links allergic rhinitis to higher risk of vision-threatening optic neuritis

Sungkyunkwan University researchers in Korea ran a nationwide cohort analysis linking allergic diseases to increased optic neuritis risk, with allergic rhinitis showing the strongest association.

Wind-blown dust from receding Salton Sea linked to reduced lung function in area children

Children living near the Salton Sea, in Southern California's desert region of Imperial County, are experiencing poorer lung function than children exposed to less wind-blown dust, according to a new study led by researchers ...

mRNA directs body to produce nanobodies that unlock immune attack on colorectal cancer tumors

A tiny molecule called a nanobody may succeed where today's cancer drugs often fail, according to University of Hawaiʻi at Mānoa researcher Stefan Moisyadi, who has been refining the concept for nearly a decade.

Bioengineering breathes new life into failed cancer treatment

Many advanced cancers develop resistance to treatment and become highly aggressive, often leaving patients with limited treatment options. In some cancers, including lung, pancreatic and prostate tumors, a key driver of treatment ...

Skin symptoms may forewarn mental health risks

Scientists have discovered that mental health patients who have skin conditions may be more at risk of worse outcomes, including suicidality and depression. This work, which may aid in identifying at-risk patients and personalizing ...

Blood cancer: Scientists reprogram cancer cell death to trigger immune system

The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a preclinical model, scientists from the Institut Pasteur and Inserm successfully stimulated an effective ...

Recommended News For You

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

Black and Hispanic children with high-risk neuroblastoma have worse outcomes despite standardized treatment

The importance of breast cancer screening

Cancer research in the US is world class. With the government pulling out, its future is uncertain

We don't all need regular skin cancer screening?but you can know your risk and check yourself

According to new studies, some cancer patients can safely forego radiation therapy.

Do I qualify for a cancer clinical trial?

Recommended Articles For You

Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts 

Mastering Prostate Cancer Care: CME, Certification, Digital Tools, and Evidence-Based Strategies 

Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology 

Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Rural residents continue to have higher odds of skin cancer, study finds

2.

FDA Authorizes Three Different Uses for Injectable Antibiotic.

3.

For MDS-Related Anemia, Telomerase Inhibitor Approved.

4.

Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis

5.

Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival

1.

New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma 

2.

Genetic Screening: A Game Changer in Cancer Prevention

3.

Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy

4.

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians

5.

Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

3.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

4.

Efficient Management of First line ALK-rearranged NSCLC - Part III

5.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot